Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Hetero gets DCGI nod...

    Hetero gets DCGI nod to market anti-retroviral FDC tablets

    Written by Ruby Khatun Khatun Published On 2017-11-17T10:45:31+05:30  |  Updated On 2021-08-18T15:31:33+05:30

    New Delhi: Drug firm Hetero said it has received the Drug Controller General of India's approval to launch generic fixed-dose combination anti-retroviral drug 'Darunavir + Ritonavir' in the country.


    The product will be marketed and distributed under the brand name 'DANAVIR-R' in India by Hetero Healthcare Ltd, the Hyderabad-based firm said in a statement.


    It will be made available in the strengths of 800/100mg, 600/100mg, and 400/50mg, it added.


    Commenting on the development, Hetero Group of Companies CMD B P S Reddy said: "Hetero is proud to extend its latest offering Darunavir+Ritonavir FDC in three strengths for HIV/AIDS patients."

    The company also looks forward to making these tablets available in other countries, subject to approvals from respective regulatory authorities, Hetero said.

    The product is an anti-retroviral medication indicated for the treatment of human immunodeficiency virus (HIV-1) in adult patients, it added.

    anti-retroviral approval DANAVIR-R Darunavir + Ritonavir DCGI Drug Controller General of India FDC tablets Fixed Dose Combination generic Hetero Hetero Healthcare Ltd HIV-1 HIV/AIDS human immunodeficiency virus Launch market 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs 9700 crore

      Sterling Biotech Bank Fraud: ED seize assets including business jet, ships, oil rings worth over Rs...

      Ipca Lab Conferred With the CARE Award

      Ipca Lab Conferred With the CARE Award

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X